重磅!葛兰素史克中枢神经系统治疗药物利必通获批双相情感障碍新适应症
GSK中国处方药和疫苗总经理齐欣女士表示:
”
双相情感障碍诊疗面临诸多挑战
识别、诊断、治疗“三率皆低”
利必通获批治疗双相情感障碍
助力提升我国双相情感障碍规范化治疗水平
王刚教授认为:
参考文献
1. 利必通获批新增适应症:“本品用于控制成人双相情感障碍患者情绪发作的复发或复燃。本品对双相情感障碍患者情绪发作的急性期治疗的有效性及安全性尚未确定。”
2. 于欣,方贻儒主编. 中国双相情感障碍防治指南(第二版).北京:中华医学电子音像出版社. 2015. P1
3. Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: across-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211-224.
4. McIntyreRS, Calabrese JR. Bipolar depression: the clinical characteristics and unmetneeds of a complex disorder. Curr Med Res Opin. 2019 Nov;35(11):1993-2005.
5. Drancourt N, Etain B, Lajnef M, et al. Duration of untreated bipolar disorder: missedopportunities on the long road to optimal treatment. Acta Psychiatr Scand.2013;127(2):136-44.
6. 于欣,方贻儒主编. 中国双相障碍防治指南(第二版).北京:中华医学电子音像出版社. 2015. P7-8
7. Najafi-Vosough R, Ghaleiha A, Faradmal J, et al. Recurrence in Patients with Bipolar Disorderand Its Risk Factors. Iran J Psychiatry. 2016;11(3):173-177.
8. Baldessarini RJ, Vázquez GH, Tondo L. Bipolar depression: a major unsolvedchallenge. Int J Bipolar Disord. 2020 Jan 6;8(1):1.
9. Goodwin GM, Bowden CL, Calabrese JR, et al. Apooled analysis of 2 placebo-controlled 18-month trials of lamotrigine andlithium maintenance in bipolar I disorder. J Clin Psychiatry.2004;65(3):432-41.